Source-grounded facts extracted from Core Scientific, Inc./tx's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Steve M. Smith was appointed as Director at Core Scientific, Inc./tx.
“On May 26, 2026, the Company announced the appointment of Steve M. Smith, as a member of the Board and the Nominating and Corporate Governance Committee of the Board, effective immediately.”
Core Scientific, Inc./tx shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-12 meeting.
“Proposal 3: To ratify the appointment of KPMG LLP”
Core Scientific, Inc./tx shareholders approved Advisory approval of named executive officer compensation as disclosed in the 2026 Proxy Statement at the 2026-05-12 meeting.
“Proposal 2: To approve on a non-binding, advisory basis, the compensation of our named executive officers”
Core Scientific, Inc./tx shareholders approved Election of five nominees to the Board of Directors at the 2026-05-12 meeting.
“Nominee For Withheld Broker Non-Votes Adam Sullivan 217,650,785 2,469,826 44,778,216 Jeff Booth 168,580,185 51,540,426 44,778,216 Elizabeth Crain 215,074,279 5,046,332 44,778,216 Yadin Rozov 213,054,408 7,066,203 44,778,216 Eric Weiss 168,947,230 51,173,381 44,778,216”
Core Scientific, Inc./tx incurred senior notes of $3.3 billion with Wilmington Savings Fund Society, FSB at 7.750% maturing May 15, 2031.
“On May 6, 2026, Core Scientific Finance I LLC (the “Issuer”), a wholly-owned indirect subsidiary of Core Scientific, Inc. (“Core Scientific”), completed its previously announced private offering (the “Offering”) of $3.3 billion aggregate principal amount of its 7.750% Senior Secured Notes due 2031 (the “Notes”).”
Core Scientific, Inc./tx reported first quarter of 2026 results: revenue $115.2 million, net income $347.2 million.
“is accelerating customer discussions and reinforcing the value of our high-density compute infrastructure platform.” First Quarter 2026 Financial Results • Total revenue was $115.2 million compared to $79.5 million in the first quarter of 2025. ◦ Colocation revenue was $77.5 million, up from $8.6 million in the first quarter of 2025, driven by incremental billable”
Core Scientific, Inc./tx entered into Indenture with Wilmington Savings Fund Society, FSB valued at $3.3 billion (effective 2026-05-06).
“the Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of May 6, 2026, between the Issuer, Holdco (as defined below), the Subsidiary Guarantors and Wilmington Savings Fund Society, FSB, as trustee (the “Trustee”) and collateral agent (the “Collateral Agent”)”
Core Scientific, Inc./tx entered into Merger Agreement with Polar Merger Sub, LLC, Polaris DS LLC, Top Access Enterprises Limited, Altair LLC valued at approximately $421 million in cash (effective 2026-05-05).
“On May 5, 2026, Core Scientific, Inc., a Delaware corporation (the “Company”), entered into an agreement and plan of merger (the “Merger Agreement”) with Polar Merger Sub, LLC, a Nevada limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Polaris DS LLC, a Nevada limited liability company (the “Target”), Top Access Enterprises Limited, a company organized under the laws of Hong Kong and sole owner of the Target (“Seller”), and solely for the purposes of Article XI (and Article I and Article VII to the extent relating thereto) of the Merger Agreement, Altair LLC, an Oklahoma limited liability company (“Parent Sub”), pursuant to which at the effective time of the statutory merger contemplated thereby, Merger Sub will merge with and into the Target (the “Acquisition”), with the Target surviving as a wholly owned subsidiary of the Company.”
Jorge Ray was appointed as Principal Accounting Officer at Core Scientific, Inc./tx.
“On April 30, 2026, the Board of Directors of Core Scientific, Inc. (the “Company”) appointed Jorge Ray as the Company’s Principal Accounting Officer, effective May 7, 2026.”
Core Scientific, Inc./tx incurred credit facility of $500.0 million incremental commitment with JPMorgan Chase Bank, N.A..
“On March 18, 2026 (the “Closing Date”), Core Scientific, Inc. (the “Company”) entered into Amendment No. 1 to Delayed-Draw Bridge Credit Agreement (the “Incremental Amendment”), by and among the Company, as borrower, Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent (in such capacity, the “Agent”), and JPMorgan Chase Bank, N.A. (“JPM”), as amendment no. 1 term lender, which amends the Company’s existing credit agreement (the “Initial Credit Agreement”) with the lenders party thereto from time to time and the Agent to increase the term loan commitments thereunder by $500.0 million, to $1.0 billion total, pursuant to the accordion feature of the Initial Credit Agreement. The Company borrowed the full $500.0 incremental commitment on the Closing Date.”
Core Scientific, Inc./tx amended Amendment No. 1 to Delayed-Draw Bridge Credit Agreement with Morgan Stanley Senior Funding, Inc. and JPMorgan Chase Bank, N.A. valued at $500.0 million (effective 2026-03-18).
“On March 18, 2026 (the “Closing Date”), Core Scientific, Inc. (the “Company”) entered into Amendment No. 1 to Delayed-Draw Bridge Credit Agreement (the “Incremental Amendment”), by and among the Company, as borrower, Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent (in such capacity, the “Agent”), and JPMorgan Chase Bank, N.A. (“JPM”), as amendment no. 1 term lender, which amends the Company’s existing credit agreement (the “Initial Credit Agreement”) with the lenders party thereto from time to time and the Agent to increase the term loan commitments thereunder by $500.0 million, to $1.0 billion total, pursuant to the accordion feature of the Initial Credit Agreement.”
Core Scientific, Inc./tx incurred term loan of $500.0 million with Morgan Stanley Senior Funding, Inc. at term SOFR (subject to a 0% floor), plus an applicable margin of 2.50% per annum maturing the date that is 364 days after the Closing Date.
“as administrative agent and collateral agent. The Credit Agreement provides for a senior secured loan facility (the “Term Loan Facility”) in an aggregate principal amount of $500.0 million. The Credit Agreement also provides for an accordion feature that allows the Company to request an increase in commitments under the Credit Agreement by up to an additional”
Core Scientific, Inc./tx entered into Credit Agreement with Morgan Stanley Senior Funding, Inc. valued at $500.0 million (effective 2026-03-04).
“On March 4, 2026 (the “Closing Date”), Core Scientific, Inc. (the “Company”) entered into a loan facility Credit Agreement (the “Credit Agreement”), by and among the Company, as borrower, the lenders party thereto from time to time (the “Lenders”) and Morgan Stanley Senior Funding, Inc. (“MSSF”), as administrative agent and collateral agent.”
Core Scientific, Inc./tx reported that prior financial statements should not be relied upon.
“On February 25, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company, in consultation with management, determined that the Company’s consolidated financial statements for the three and six months ended June 30, 2024, the three and nine months ended September 30, 2024, the year ended December 31, 2024, the three months ended March 31, 2025, the three and six months ended June 30, 2025, and the three and nine months ended September 30, 2025 (the “Non-Reliance Periods”) should no longer be relied upon due to the accounting errors described below.”
Core Scientific, Inc./tx entered into Cooperation Agreement with Two Seas Capital LP (effective 2026-02-18).
“On February 18, 2026, Core Scientific, Inc., a Delaware corporation (the “Company”) entered into a cooperation agreement (the “Cooperation Agreement”) with Two Seas Capital LP (“Two Seas”).”
Core Scientific, Inc./tx entered into Cooperation Agreement with Two Seas Capital LP (effective 2026-02-18).
“On February 18, 2026, Core Scientific, Inc., a Delaware corporation (the “Company”), entered into a cooperation agreement (the “Cooperation Agreement”) with Two Seas Capital LP (“Two Seas”).”
Core Scientific, Inc./tx: Amended and restated bylaws to conform to charter amendments, revise procedural mechanics for stockholder nominations and proposals, and make ministerial changes (effective 2025-05-27).
“the Board approved, contingent and effective upon stockholder approval of the Approved Proposals and effectiveness of the Fourth Amended and Restated Certificate of Incorporation, the amendment and restatement of the Company’s Second Amended and Restated Bylaws”
Core Scientific, Inc./tx: Eliminated classified board, removed supermajority vote requirement, and eliminated creditor consent rights upon emergence from bankruptcy, effective upon filing of Fourth Amended and Restated Certificate of Incorporation (effective 2025-05-27).
“the stockholder-approved amendments to the Certificate of Incorporation became effective upon the filing of the Fourth Amended and Restated Certificate of Incorporation on May 27, 2025 with the Secretary of State of Delaware.”
Elizabeth Crain was appointed as Director at Core Scientific, Inc./tx.
“On May 14, 2025, the Board appointed Elizabeth Crain as a member of the Board and the Chair of the Audit Committee of the Board, effective immediately.”
Todd Becker resigned as Director at Core Scientific, Inc./tx.
“On May 13, 2025, Todd Becker informed the Board of Directors (the “Board”) of Core Scientific, Inc. (the “Company”) of his resignation as a member of the Board and the applicable committees thereof, effective immediately.”
Core Scientific, Inc./tx engaged KPMG LLP as its auditor.
“approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the year ending December 31, 2025, effective immediately.”
Core Scientific, Inc./tx dismissed Marcum LLP as its auditor.
“Marcum LLP (“Marcum”), the Company’s prior independent registered public accounting firm, was informed on March 12, 2025 that it was dismissed as the Company’s independent registered public accounting firm.”
James P. Nygaard, Jr. was appointed as Executive Vice President, Chief Financial Officer at Core Scientific, Inc./tx.
“On March 2, 2025, the Board of Directors (the “Board”) of Core Scientific, Inc. (the “Company”) approved the appointment of James P. Nygaard, Jr., age 50, as the Company’s Executive Vice President, Chief Financial Officer, effective March 17, 2025.”
Denise Sterling departed as Executive Vice President and Chief Financial Officer at Core Scientific, Inc./tx.
“On September 5, 2024, Denise Sterling, Executive Vice President and Chief Financial Officer of the Company, informed the Company of her intention to resign from the Company pending the appointment of a successor.”
Core Scientific, Inc./tx reported fourth fiscal quarter and full year ended December 31, 2023 results: revenue $141.9 million, net income Net loss of $195.7 million.
“reported its financial results for the fiscal fourth quarter and year ended December 31, 2023. Fiscal Fourth Quarter 2023 Compared to Fiscal Fourth Year 2022 • Total revenue of $141.9 million, an increase of $20.7 million • Net loss of $195.7 million, an improvement of $239.2 million • Adjusted EBITDA of $57.5 million, an increase of $51.2 million Fiscal Year 2023”
Core Scientific, Inc./tx: Company adopted Second Amended and Restated Bylaws on the Effective Date (effective 2024-01-25).
“On the Effective Date, in accordance with the Plan, the Company will file the Third Amended and Restated Certificate of Incorporation (the “ COI ”) with the Secretary of State of the State of Delaware and adopt the Second Amended and Restated Bylaws (the “ Bylaws ”).”
Core Scientific, Inc./tx: Company filed Third Amended and Restated Certificate of Incorporation on the Effective Date (effective 2024-01-25).
“On the Effective Date, in accordance with the Plan, the Company will file the Third Amended and Restated Certificate of Incorporation (the “ COI ”) with the Secretary of State of the State of Delaware and adopt the Second Amended and Restated Bylaws (the “ Bylaws ”).”
Core Scientific, Inc./tx entered into New Miner Equipment Lender Agreements (Election 2) with each Holder of an Allowed Miner Equipment Lender Secured Claim that is a Settling Miner Equipment Lender that elected on its Ballot to receive and is receiving the Miner Equipment Lender Treatment Election 2 (effective 2024-01-23).
“under the terms of the Plan, the Company entered into separate New Miner Equipment Lender Agreements (Election 2) with each Holder of an Allowed Miner Equipment Lender Secured Claim that is a Settling Miner Equipment Lender that elected on its Ballot (as defined in the RSA) to receive and is receiving the Miner Equipment Lender Treatment Election 2”
Core Scientific, Inc./tx entered into Exit Credit Agreement with Wilmington Trust, National Association, as administrative agent and collateral agent, and the lenders party thereto valued at $80 million (effective 2024-01-23).
“under the terms of the Plan, the Company entered into a credit and guaranty agreement, dated as of January 23, 2024 (the “ Exit Credit Agreement ”), by and among the Company, as borrower, the guarantors named therein, the lenders party thereto and Wilmington Trust, National Association, as administrative agent and collateral agent, consisting of an $80 million first-lien credit facility”
Eric Weiss was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Yadin Rozov was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Jarrod Patten was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Jordan Levy was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Jeffrey Booth was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Todd Becker was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Adam Sullivan was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss (collectively, the “ New Board Members ”).”
Kneeland Youngblood resigned as Director at Core Scientific, Inc./tx.
“Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matthew Minnis, Neal Goldman and Kneeland Youngblood resigned from the board of directors (the “ Board ”).”
Neal Goldman resigned as Director at Core Scientific, Inc./tx.
“Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matthew Minnis, Neal Goldman and Kneeland Youngblood resigned from the board of directors (the “ Board ”).”
Matthew Minnis resigned as Director at Core Scientific, Inc./tx.
“Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matthew Minnis, Neal Goldman and Kneeland Youngblood resigned from the board of directors (the “ Board ”).”
Jarvis Hollingsworth resigned as Director at Core Scientific, Inc./tx.
“Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matthew Minnis, Neal Goldman and Kneeland Youngblood resigned from the board of directors (the “ Board ”).”
Darin Feinstein resigned as Director at Core Scientific, Inc./tx.
“Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matthew Minnis, Neal Goldman and Kneeland Youngblood resigned from the board of directors (the “ Board ”).”
Michael Levitt resigned as Director at Core Scientific, Inc./tx.
“Michael Levitt, Darin Feinstein, Jarvis Hollingsworth, Matthew Minnis, Neal Goldman and Kneeland Youngblood resigned from the board of directors (the “ Board ”).”
Core Scientific, Inc./tx: Filing of Third Amended and Restated Certificate of Incorporation on the Effective Date.
“On the Effective Date, in accordance with the Plan, the Company will file the Third Amended and Restated Certificate of Incorporation (the “ COI ”) with the Secretary of State of the State of Delaware and adopt the Second Amended and Restated Bylaws (the “ Bylaws ”).”
Core Scientific, Inc./tx: Adoption of Second Amended and Restated Bylaws on the Effective Date.
“On the Effective Date, in accordance with the Plan, the Company will file the Third Amended and Restated Certificate of Incorporation (the “ COI ”) with the Secretary of State of the State of Delaware and adopt the Second Amended and Restated Bylaws (the “ Bylaws ”).”
Core Scientific, Inc./tx entered into Secured Convertible Notes Indenture with guarantors party thereto and Wilmington Trust, National Association, as trustee and as collateral agent valued at $260.0 million aggregate principal amount of secured convertible notes due 2029 (effective 2024-01-23).
“On the Effective Date, under the terms of the Plan, the Company issued $260.0 million aggregate principal amount of secured convertible notes due 2029 (the “ Secured Convertible Notes ”) pursuant to a secured convertible notes indenture (the “ Secured Convertible Notes Indenture ”) among (i) Core Scientific, Inc., as the issuer, (ii) the guarantors party thereto and (iii) Wilmington Trust, National Association, as trustee and as collateral agent for the Secured Convertible Notes”
Core Scientific, Inc./tx entered into New Miner Equipment Lender Agreements (Election 2) with Holders of Allowed Miner Equipment Lender Secured Claims that are Settling Miner Equipment Lenders electing Election 2 valued at principal amount of eighty percent (80%) of each applicable Holders’ Allowed Miner Equipment Lender (effective 2024-01-23).
“On the Effective Date, under the terms of the Plan, the Company entered into separate New Miner Equipment Lender Agreements (Election 2) with each Holder of an Allowed Miner Equipment Lender Secured Claim that is a Settling Miner Equipment Lender that elected on its Ballot (as defined in the RSA) to receive and is receiving the Miner Equipment Lender Treatment Election 2”
Core Scientific, Inc./tx entered into Exit Credit Agreement with lenders party thereto and Wilmington Trust, National Association, as administrative agent and collateral agent valued at $80 million first-lien credit facility (effective 2024-01-23).
“On the Effective Date, under the terms of the Plan, the Company entered into a credit and guaranty agreement, dated as of January 23, 2024 (the “ Exit Credit Agreement ”), by and among the Company, as borrower, the guarantors named therein, the lenders party thereto and Wilmington Trust, National Association, as administrative agent and collateral agent, consisting of an $80 million first-lien credit facility”
Eric Weiss was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss”
Yadin Rozov was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss”
Jarrod Patten was appointed as Director at Core Scientific, Inc./tx.
“As of the Effective Date, the Board consists of the following seven directors, who were appointed in accordance with the Plan: Adam Sullivan, Todd Becker, Jeffrey Booth, Jordan Levy, Jarrod Patten, Yadin Rozov and Eric Weiss”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.